{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Ligand Pharmaceuticals, Inc.
Ligand Pharmaceuticals Hits Day High with 9.91% Surge in Stock Price
Ligand Pharmaceuticals, Inc. saw a notable increase in stock performance on November 6, 2025, reaching an intraday high. The company has outperformed the S&P 500 over various periods, but it faces challenges such as negative net profit and low return on capital, raising concerns about its long-term viability.
Ligand Pharmaceuticals Hits New 52-Week High of $211.91
Ligand Pharmaceuticals, Inc. has achieved a new 52-week high, highlighting its strong performance in the Pharmaceuticals and Biotechnology sector. The company has seen significant stock price growth over the past year, outpacing the S&P 500, despite being loss-making and having no dividend yield.
Ligand Pharmaceuticals Hits New 52-Week High of $189.60
Ligand Pharmaceuticals, Inc. achieved a new 52-week high of USD 189.60 on October 24, 2025, reflecting a significant increase in its stock price over the past year. With a market capitalization of USD 3,250 million, the company remains unprofitable and does not offer dividends, typical for growth-focused biotech firms.
Ligand Pharmaceuticals Hits New 52-Week High of $186.40
Ligand Pharmaceuticals, Inc. achieved a new 52-week high of USD 186.40 on October 8, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen significant stock price growth over the past year, despite being loss-making, with notable financial metrics indicating its market positioning.
Ligand Pharmaceuticals Hits New 52-Week High of $184.26
Ligand Pharmaceuticals, Inc. achieved a new 52-week high of USD 184.26 on October 6, 2025, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen significant stock price growth over the past year, despite being loss-making and having a negative return on equity.
Ligand Pharmaceuticals Hits New 52-Week High of $183.81
Ligand Pharmaceuticals, Inc. achieved a new 52-week high of USD 183.81 on October 3, 2025, reflecting a significant increase in stock performance over the past year. Despite this milestone, the company remains unprofitable, with a negative return on equity and no dividend yield.
Ligand Pharmaceuticals Hits New 52-Week High of $181.62
Ligand Pharmaceuticals, Inc. achieved a new 52-week high of USD 181.62 on October 1, 2025, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen significant growth over the past year, with a notable increase in stock price, despite being loss-making and not offering dividends.
Ligand Pharmaceuticals Hits New 52-Week High at $177.77
Ligand Pharmaceuticals, Inc. achieved a new 52-week high of USD 177.77 on September 30, 2025, reflecting strong performance in the pharmaceuticals sector. The company has seen a significant stock price increase over the past year, despite being loss-making, and maintains a focus on growth and reinvestment.
Ligand Pharmaceuticals Hits New 52-Week High of $172.45
Ligand Pharmaceuticals, Inc. achieved a new 52-week high of USD 172.45 on September 22, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. Over the past year, the company has gained 114.72%, despite facing challenges with a negative return on equity and a loss-making position.
Is Ligand Pharmaceuticals, Inc. technically bullish or bearish?
As of July 18, 2025, Ligand Pharmaceuticals has a bullish technical trend supported by positive MACD and Bollinger Bands indicators, despite a bearish weekly RSI, and has significantly outperformed the S&P 500 year-to-date and over the past year.
Is Ligand Pharmaceuticals, Inc. overvalued or undervalued?
As of February 27, 2025, Ligand Pharmaceuticals is considered overvalued with high valuation ratios and negative returns on capital and equity, despite a strong year-to-date stock performance of 58.50%.
Ligand Pharmaceuticals Hits New 52-Week High of $170.78
Ligand Pharmaceuticals, Inc. achieved a new 52-week high of USD 170.78 on September 18, 2025, reflecting strong performance in the Pharmaceuticals & Biotechnology sector. The company has seen a 113.54% growth over the past year, despite being loss-making and focusing on reinvestment rather than dividends.
Is Ligand Pharmaceuticals, Inc. technically bullish or bearish?
As of June 27, 2025, the trend is mildly bullish due to positive indicators like a bullish MACD and Bollinger Bands, although daily moving averages suggest a slightly bearish outlook, creating some mixed signals overall.
Is Ligand Pharmaceuticals, Inc. technically bullish or bearish?
As of June 17, 2025, the technical trend is neutral with mixed indicators: the weekly MACD is bullish, the monthly MACD is mildly bearish, and while Bollinger Bands suggest potential upward movement, daily moving averages are mildly bearish, leading to a lack of strong signals overall.
Is Ligand Pharmaceuticals, Inc. overvalued or undervalued?
As of February 27, 2025, Ligand Pharmaceuticals is considered overvalued and risky due to negative earnings and poor return metrics, with a P/E ratio of -27.37, despite a recent 44.82% stock return that outperformed the S&P 500.
Who are in the management team of Ligand Pharmaceuticals, Inc.?
As of March 2022, the management team of Ligand Pharmaceuticals, Inc. includes Dr. John Kozarich (Non-Executive Independent Chairman), Mr. John Higgins (CEO and Director), and several Independent Directors: Mr. Jason Aryeh, Ms. Sarah Boyce, Mr. Todd Davis, and Dr. Nancy Gray. This team provides governance and strategic direction for the company.
What does Ligand Pharmaceuticals, Inc. do?
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that develops and acquires technologies to aid in drug discovery and development. As of March 2025, it reported net sales of $45 million and a net loss of $42 million, with a market cap of approximately $2.17 billion.
How big is Ligand Pharmaceuticals, Inc.?
As of Jun 18, Ligand Pharmaceuticals, Inc. has a market capitalization of $2.17 billion, with net sales of $181.48 million and a net profit of -$132.62 million over the last four quarters. Shareholder's funds are reported at $830.44 million, and total assets amount to $941.77 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
